e) lack mortality benefit and may worsen hf. hctz (c) is not indicated for mortality reduction. ivabradine (d)

Instant feedback + full explanation. One question, done properly.

A 70-year-old with HFrEF (EF 25%) is on ARNI, beta-blocker, and SGLT2 inhibitor. Persistent albuminuria 200 mg/g. Which additional mortality-reducing therapy should be added?

Educational content. Not a substitute for clinical judgement or local policy.

e) lack mortality benefit and may worsen hf. hctz (c) is not indicated